CytomX Therapeutics CTMX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $28.83M+128% | $12.67M-62.9% | $34.19M-30.3% | $49.04M+3.0% | $47.6M+25.1% | ||
| $317.88M+156% | $124.39M+13.7% | $109.44M+0.4% | $109.05M+238% | $32.28M-48.4% | ||
| $1.53M0.0% | $1.53M+48.5% | $1.03M0.0% | $1.03M0.0% | $1.03M+0.1% | ||
| $646K-67.9% | $2.01M+23.6% | $1.63M-12.8% | $1.87M-4.4% | $1.96M-37.0% | ||
| $5.74M+18.3% | $4.86M+22.6% | $3.96M-15.1% | $4.67M-2.5% | $4.79M+33.7% | ||
| $353.1M+145% | $143.92M-3.5% | $149.22M-9.4% | $164.62M+90.0% | $86.63M-19.3% | ||
| $1.09M-16.4% | $1.3M-24.2% | $1.72M-11.6% | $1.95M-12.7% | $2.23M-9.6% | ||
| $2.26M-33.3% | $3.4M-29.5% | $4.81M-19.1% | $5.95M-15.7% | $7.06M-13.3% | ||
| $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | $949K0.0% | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% | ||
| $31K0.0% | $31K-39.2% | $51K-8.9% | $56K-8.2% | $61K-7.6% | ||
| $359.36M+137% | $151.57M-4.2% | $158.25M-9.6% | $175.06M+77.7% | $98.5M-18.3% | ||
| $1.37M+5.1% | $1.3M+101% | $646K+185% | $227K-17.8% | $276K-74.6% | ||
| $11.92M-16.0% | $14.2M+14.4% | $12.41M+7.9% | $11.5M+0.9% | $11.41M-7.6% | ||
| $17.88M-33.5% | $26.88M+20.1% | $22.38M+1.5% | $22.05M-33.6% | $33.23M-50.6% | ||
| $2.86M-32.6% | $4.24M-24.2% | $5.6M+2.8% | $5.44M+2.8% | $5.29M+2.9% | ||
| $979K-38.4% | $1.59M-71.3% | $5.54M-45.9% | $10.24M-36.8% | $16.21M-39.6% | ||
| $34.02M-27.0% | $46.62M+13.6% | $41.03M+4.6% | $39.22M-21.9% | $50.2M-41.5% | ||
| $4.41M+1.4% | $4.35M+1.3% | $4.3M+1.4% | $4.24M+1.5% | $4.18M+1.5% | ||
| $39.41M-25.0% | $52.56M+3.3% | $50.87M-7.8% | $55.15M-24.9% | $73.45M-39.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K+100% | $1K0.0% | ||
| $1.05B+29.5% | $810.84M+2.7% | $789.72M+0.2% | $788.08M+13.7% | $693.1M+0.3% | ||
| -$730.2M-2.6% | -$711.95M-4.3% | -$682.44M-2.1% | -$668.21M0.0% | -$668.05M+3.4% | ||
| $102K-8.1% | $111K+6.7% | $104K+215% | $33K+3,400% | -$1K-104% | ||
| $319.94M+223% | $99.01M-7.8% | $107.39M-10.4% | $119.91M+379% | $25.05M+5,593% | ||
| $359.36M+137% | $151.57M-4.2% | $158.25M-9.6% | $175.06M+77.7% | $98.5M-18.3% | ||
| $317.88M+156% | $124.39M+13.7% | $109.44M+0.4% | $109.05M+238% | $32.28M-48.4% | ||
| $31K0.0% | $31K-39.2% | $51K-8.9% | $56K-8.2% | $61K-7.6% | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% | ||
| $2.26M-33.3% | $3.4M-29.5% | $4.81M-19.1% | $5.95M-15.7% | $7.06M-13.3% | ||
| $2.26M-33.3% | $3.4M-29.5% | $4.81M-19.1% | $5.95M-15.7% | $7.06M-13.3% | ||
| $31K0.0% | $31K-39.2% | $51K-8.9% | $56K-8.2% | $61K-7.6% | ||
| $2.26M-33.3% | $3.4M-29.5% | $4.81M-19.1% | $5.95M-15.7% | $7.06M-13.3% | ||
| $31K0.0% | $31K-39.2% | $51K-8.9% | $56K-8.2% | $61K-7.6% | ||
| $979K-38.4% | $1.59M-71.3% | $5.54M-45.9% | $10.24M-36.8% | $16.21M-39.6% | ||
| $11.92M-16.0% | $14.2M+14.4% | $12.41M+7.9% | $11.5M+0.9% | $11.41M-7.6% | ||
| $11.92M-16.0% | $14.2M+14.4% | $12.41M+7.9% | $11.5M+0.9% | $11.41M-7.6% | ||
| $979K-38.4% | $1.59M-71.3% | $5.54M-45.9% | $10.24M-36.8% | $16.21M-39.6% | ||
| $979K-38.4% | $1.59M-71.3% | $5.54M-45.9% | $10.24M-36.8% | $16.21M-39.6% | ||
| $2.86M-32.6% | $4.24M-24.2% | $5.6M-18.7% | $6.89M-15.5% | $8.15M-13.2% | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K+100% | $1K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $401K-8.4% | $438K-7.6% | $474K-7.1% | $510K-6.8% | $547K-6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CytomX Therapeutics's total assets?
- CytomX Therapeutics (CTMX) holds $359.4M in total assets, up 264.8% year over year.
- How much debt does CytomX Therapeutics have?
- CytomX Therapeutics carries $2.9M in total debt against $319.9M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does CytomX Therapeutics have?
- CytomX Therapeutics holds $28.8M in cash and equivalents.
- Can CytomX Therapeutics cover its short-term obligations?
- Its current ratio is 10.38 — current assets exceed current liabilities.
- Where does CytomX Therapeutics's balance sheet data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
